natgillin/translations-raw huggingface dataset:
23% af patienterne havde light chain disease, og 12% havde kun målbar sygdom ved free light chain assay. 
Twenty three percent of patients had light chain disease and 12% of patients had measurable disease by free light chain assay only.
Da NINLARO anvendes i kombination med lenalidomid, skal du overholde programmet for forebyggelse af graviditet, der gælder for lenalidomid, fordi lenalidomid kan være skadeligt for det ufødte barn. 
As NINLARO is given in combination with lenalidomide, you should adhere to the pregnancy prevention programme of lenalidomide because lenalidomide can be harmful to the unborn child.
Ixazomib er til oral anvendelse. 
Ixazomib is for oral use.
Det gennemsnitlige AUC var 35% højere hos asiatiske patienter, men der var overlap i AUC for ixazomib på tværs af hvide og asiatiske patienter. 
The mean AUC was 35% higher in Asian patients; however, there was overlap in the AUC of ixazomib across White and Asian patients.
25% af patienterne havde kreatininclearance på < 60 ml/min. 
Twenty five percent of patients had a creatinine clearance of < 60 mL/min.
Hvis du har taget for meget NINLARO, skal du tale med en læge eller tage direkte på hospitalet. 
If you take more NINLARO than you should, talk to a doctor or go to a hospital straight away.
77% af patienterne recidiverede efter tidligere behandlinger, og 11% var refraktære over for tidligere behandlinger. 
Seventy seven percent of patients relapsed after prior therapies and 11% were refractory to prior therapies.
Hvis en patient kaster op efter at have taget en dosis, skal patienten ikke tage en ny dosis, men genoptage doseringen på tidspunktet for den næste planlagte dosis. 
If a patient vomits after taking a dose, the patient should not repeat the dose but should resume dosing at the time of the next scheduled dose.
NINLARO kan påvirke din evne til at køre motorkøretøj og betjene maskiner. 
NINLARO may affect your ability to drive or use machines.
• kvalme, opkastning og diarré 
• nausea, vomiting and diarrhoea
Ved den primære analyse (median opfølgning på 14,7 måneder og et mediant antal cyklusser på 13) var PFS statistisk signifikant forskellig mellem de to behandlingsarme. 
At the primary analysis (median follow up of 14.7 months and a median of 13 cycles), PFS was statistically significantly different between the treatment arms.
Der er ikke udført studier af fertilitet og tidlig fosterudvikling eller præ- og postnatal toksikologiske studier med ixazomib, men reproduktionsvæv blev evalueret i de generelle toksicitetsstudier. 
Studies of fertility and early embryonic development and pre- and post-natal toxicology were not conducted with ixazomib, but evaluation of reproductive tissues was conducted in the general toxicity studies.
Andre bivirkninger Fortæl det til din læge eller apotekspersonalet, hvis nogen af nedenstående bivirkninger bliver svære. 
Other possible side effects Tell your doctor or pharmacist if any of the side effects below become severe.
Der er ingen kendt specifik antidot mod overdosering af ixazomib. 
There is no known specific antidote for ixazomib overdose.
Efter oral indgivelse viste et studie af vævsfordelingen af ixazomib hos rotter, at hjernen og rygmarven var blandt de væv, der havde de laveste niveauer, hvilket tyder på, at penetrationen af ixazomib gennem blod-hjerne-barrieren synes at være begrænset. 
Following oral administration, a tissue distribution study in rats revealed that the brain and spinal cord were amongst the tissues with the lowest levels, suggesting that the penetration of ixazomib through the blood-brain barrier appears to be limited.
PRES er en sjælden, reversibel neurologisk lidelse, som kan vise sig med krampeanfald, hypertension, hovedpine, ændret bevidsthedsniveau og synsforstyrrelser. 
PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, altered consciousness, and visual disturbances.
Thalidomid er et aktivt stof, som er teratogent hos mennesker, og som forårsager alvorlige livstruende medfødte misdannelser. 
Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.
Patienter, der skiftede behandling før sygdomsprogression, var kvalificerede til at deltage, ligesom patienter med kontrolleret kardiovaskulær sygdom var det. 
Patients that changed therapies prior to disease progression were eligible for enrolment, as well as those with controlled cardiovascular conditions.
Hvis ixazomib anvendes under graviditet, eller hvis patienten bliver gravid, mens hun tager ixazomib, skal patienten informeres om den potentielle risiko for fostret. 
If ixazomib is used during pregnancy or if the patient becomes pregnant while taking ixazomib, the patient should be apprised of the potential hazard to the foetus.
Ixazomib forårsagede kun embryo-føtal toksicitet hos drægtige rotter og kaniner ved maternelt toksiske doser og ved eksponeringer, som var lidt højere end observeret hos patienter, der fik den anbefalede dosis. 
Ixazomib caused embryo-foetal toxicity in pregnant rats and rabbits only at maternally toxic doses and at exposures that were slightly higher than those observed in patients receiving the recommended dose.
Da myelomatose er en heterogen sygdom, kan fordelene variere i de forskellige undergrupper i fase 3-studiet (se Figur 2). 
As multiple myeloma is a heterogeneous disease, benefit may vary across subgroups in the Phase 3 study (C16010) (see Figure 2).
Figur 1: Kaplan-Meier kurver over progressionsfri overlevelse i ITT-populationen 
Figure 1: Kaplan-Meier plot of progression-free survival in the intent-to-treat population
Ixazomibcitrat er et pro-drug, der under fysiologiske betingelser hurtigt hydrolyseres til dets biologisk aktive form, ixazomib. 
Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses under physiological conditions to its biologically active form, ixazomib.
19% havde højrisiko cytogenetiske abnormiteter (del[17], t[4;14], t[14;16]) N = 137), 10% havde del(17) (N = 69), og 34% havde 1q amplifikation (1q21) (N = 247). 
Nineteen percent had high-risk cytogenetic abnormalities (del[17], t[4;14], t[14;16]) (N=137), 10% had del(17) (N=69) and 34% had 1q amplification (1q21) (N=247).
Ikke-kliniske farmakologiske sikkerhedsstudier, både in vitro (på hERG-kanaler) og in vivo (på telemetriovervågede hunde efter en enkelt oral indgivelse) viste ingen indvirkning af ixazomib på kardiovaskulære og respiratoriske funktioner ved AUC på mere end 8 gange den kliniske værdi. 
Non-clinical safety pharmacology studies both in vitro (on hERG channels) and in vivo (in telemetered dogs following single oral administration) demonstrated no effects of ixazomib on cardiovascular or respiratory functions at AUC more than 8-fold higher than the clinical value.
Hvis kapslen går i stykker, skal du tørre pulveret op og passe på, at det ikke hvirvles op i luften. 
If the capsule breaks, clean up the powder, taking care that it does not cause dust in the air.
Hvis du glemmer at tage NINLARO 
If you forget to take NINLARO
Gastrointestinal toksicitet 
Gastrointestinal toxicities
Andre ikke-hæmatologiske toksiciteter Andre grad 3 eller 4 ikke-hæmatologiske toksiciteter 
Other Grade 3 or 4 non-haematological toxicities
Behandling af myelomatose skal slå myelomcellerne ihjel og reducere sygdommens symptomer. 
Treatment for multiple myeloma involves killing myeloma cells and reducing the symptoms of the disease.
Responsvarighed§, måneder Median 
Duration of Response§, months Median
Fortæl det også straks til en læge, hvis du bemærker nogen af følgende s jældne bivirkninger, som kan forekomme hos op til 1 ud af 1.000 personer: 
Additionally, tell a doctor immediately if you notice any of these following rare side effects which may affect up to 1 in 1,000 people:
Toksikologiske og/eller farmakologiske studier hos dyr 
Animal toxicology and/or pharmacology
Metabolisering via flere CYP-enzymer og ikke-CYP-proteiner forventes at være den vigtigste clearancemekanisme for ixazomib. 
Metabolism by multiple CYP enzymes and non-CYP proteins is expected to be the major clearance mechanism for ixazomib.
Et randomiseret, dobbeltblindet, placebokontrolleret fase 3-studie blev gennemførtudført i Kina (N = 115) med samme studiedesign og egnethedskriterier. 
A randomised, double-blind, placebo-controlled Phase 3 study was conducted in China (N=115) with a similar study design and eligibility criteria.
Ixazomib var positiv i en in vitro klastogenicitetstest i humane perifere blodlymfocytter. 
Ixazomib was positive in an in vitro clastogenicity test in human peripheral blood lymphocytes.
Uomdannet ixazomib udgjorde < 3,5% af den indgivne dosis, der blev genfundet i urinen. 
Unchanged ixazomib accounted for < 3.5% of the administered dose recovered in urine.
Evidensen vurderes følgelig at indikere, at ixazomib ikke repræsenterer en genotoksisk risiko. 
Therefore, the weight of evidence indicates that ixazomib is not considered to present a genotoxic risk.
Posteriort reversibelt encefalopati-syndrom (PRES) er forekommet hos patienter, der fik ixazomib. 
Posterior reversible encephalopathy syndrome (PRES) has occurred in patients receiving ixazomib.
 = Indtagelse af lægemidlet 
= intake of medicinal product
• Trombocyttal skal være ≥ 75.000/mm3 
• Platelet count should be ≥ 75,000/mm3
Ixazomibbehandling havde ingen indvirkning på hanlige eller hunlige forplantningsorganer i studier af op til 6 måneders varighed hos rotter og af op til 9 måneders varighed hos hunde. 
There were no effects due to ixazomib treatment on male or female reproductive organs in studies up to 6-months duration in rats and up to 9-months duration in dogs.
Ixazomib forventes ikke at forårsage lægemiddelinteraktioner via CYP-hæmning eller -induktion. 
Ixazomib is not expected to produce drug-drug interactions via CYP inhibition or induction.
Ixazomibs sikkerhed og virkning hos børn under 18 år er ikke klarlagt. 
The safety and efficacy of ixazomib in children below 18 years of age have not been established.
Kvinder skal undgå at blive gravide, mens de er i behandling med ixazomib. 
Women should avoid becoming pregnant while being treated with ixazomib.
Ved ugentlig oral dosering blev der dag 15 observeret ca. 2-fold akkumulering i AUC. 
Approximately 2-fold accumulation in AUC was observed with weekly oral dosing on Day 15.
Ixazomib skal tages på omtrent samme tidspunkt dag 1, 8 og 15 i hver behandlingscyklus og mindst 1 time før eller 2 timer efter indtagelse af føde (se pkt. 
Ixazomib should be taken at approximately the same time on days 1, 8, and 15 of each treatment cycle at least 1 hour before or at least 2 hours after food (see section 5.2).
Livskvaliteten, vurderet på grundlag af score for overordnet helbredsstatus (EORTC QLQ-C30 og MY-20), blev bevaret under behandlingen og var sammenlignelig i de to grupper i fase 3-studiet (C16010). 
Quality of life as assessed by global health scores (EORTC QLQ-C30 and MY-20) was maintained during treatment and was similar in both treatment regimens in the Phase 3 study (C16010).
Undgå at køre motorkøretøj og betjene maskiner, hvis du får disse bivirkninger. 
Do not drive or operate machines if you have these side effects.
Fortæl det straks til din læge eller på apoteket, hvis du får nogen af følgende alvorlige meget almindelige bivirkninger, som kan forekomme hos flere end 1 ud af 10 personer: 
Tell your doctor or pharmacist straight away if you notice any of these following very common serious side effects which may affect more than 1 in 10 people:
Ixazomib Lenalidomid 
Ixazomib Lenalidomide
Proteasomer er strukturer inde i cellen, der nedbryder proteiner, og er vigtige for cellens overlevelse. 
These are structures inside the cell that digest proteins and are important for cell survival.
Medbring emballagen til lægemidlet. 
Take the medicine pack with you.
Den hyppigst rapporterede bivirkning var perifer sensorisk neuropati (16% og 12% i henholdsvis ixazomib- og placebogruppen). 
The most commonly reported reaction was peripheral sensory neuropathy (16% and 12% in the ixazomib and placebo regimen, respectively).
 Dagligt  Dagligt  Dagligt Dexamethason  
 Daily  Daily  Daily Dexamethasone 
Hvis du er en kvinde i den fødedygtige alder eller en mand, der kan blive far til et barn, skal du benytte sikker prævention under behandlingen og i mindst 90 dage efter, behandlingen er afsluttet. 
If you are a woman of childbearing potential or a man who can father a child, you must use effective contraception during and for 90 days after treatment.
I begge grupper havde under 1% af patienterne trombocyttal ≤ 5.000/mm3 under behandlingen. 
Less than 1% of patients in both regimens had a platelet count ≤ 5,000/mm3 during treatment.
• Det absolutte neutrofiltal skal være ≥ 1.000/mm3 
• Absolute neutrophil count should be ≥ 1,000/mm3
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTER TIL MAPPE 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOR WALLET
93% af patienterne havde ECOG-performancestatus 0-1, og 12% havde ISS-stadie III ved baseline (N = 90). 
Ninety three percent of patients had an ECOG performance status of 0-1 and 12% had baseline ISS stage III disease (N=90).
Mange af de patienter, der var inkluderet i forsøget, havde fremskreden sygdom med Durie-Salmon stadie III (69%) ved den initialt stillede diagnose og en behandlingshistorik med mindst to foregående behandlinger (60%) samt status som thalidomidrefraktær (63%). 
Many of the patients enrolled in the study had advanced disease with Durie-Salmon Stage III (69%) at initial diagnosis and a treatment history of receiving at least 2 prior therapies (60%) and being thalidomide refractory (63%).
• synsforstyrrelser, ændringer i mental tilstand eller krampeanfald (posteriort reversibelt encefalopati-syndrom) 
• changes in vision, changes in mental status, or seizures (posterior reversible encephalopathy syndrome)
Dag 8 Dag 9 til 14 
Day 8 Days 9 to 14
Brug ikke lægemidlet efter den udløbsdato, der står på blisteren, blistermappen og pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the blister, wallet and carton after EXP.
Alvorlige bivirkninger er rapporteret hos ≥ 2% af patienterne og omfattede trombocytopeni (2%) og diarré (2%). 
Serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhoea (2%).
ixazomib er ikke dialyserbart og kan derfor gives uden hensyntagen til tidsplanen for dialyse (se pkt. 
Ixazomib is not dialyzable and, therefore, can be administered without regard to the timing of dialysis (see section 5.2).
Da myelomceller danner mange proteiner, kan blokering af proteasomers virkning slå kræftcellerne ihjel. 
Because myeloma cells produce a lot of proteins, blocking the action of proteasomes can kill the cancerous cells.
De fleste fund for målorganerne viste delvis til fuld restitution efter seponering med undtagelse af neuronale fund i den lumbale dorsale rodganglie og rygsøjlen. 
The majority of target organ findings demonstrated partial to full recovery following discontinuation of treatment, with the exception of neuronal findings in the lumbar dorsal root ganglion and dorsal column.
Husk især at fortælle lægen, apotekspersonalet eller sygeplejersken, hvis du tager et af følgende lægemidler: carbamazepin, phenytoin, rifampicin og perikon (Hypericum perforatum). 
In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines: carbamazepine, phenytoin, rifampicin and St. John's wort (Hypericum perforatum).
I 9-måneders studiet (10 cyklusser), hvor hunde fik lægemidlet oralt efter et doseringsskema, der efterlignede det kliniske regime (28-dages cyklus), var de mikroskopiske neuronale fund generelt minimale og blev kun observeret ved 0,2 mg/kg (4 mg/m2). 
In the 9-month study (10 cycles) in dogs orally administered with a dosing schedule mimicking the clinical regimen (28-day cycle), microscopic neuronal effects were generally minimal in nature and only observed at 0.2 mg/kg (4 mg/m2).
Blod og lymfesystem Trombocytopeni* 
Blood and lymphatic system disorders Thrombocytopenia*
Spørg apoteketspersonalet, hvordan du skal bortskaffe medicinrester. 
Ask your pharmacist how to throw away medicines you no longer use.
Meget almindelige bivirkninger, som kan forekomme hos flere end 1 ud af 10 personer: 
Very common side effects may affect more than 1 in 10 people:
Uden for fase 3-studiet blev følgende alvorlige bivirkninger rapporteret sjældent: akut febril neutrofil dermatose (Sweets syndrom), Stevens-Johnsons syndrom, transversel myelitis, posteriort reversibelt encefalopati-syndrom, tumorlysesyndrom og trombotisk trombocytopenisk purpura. 
Outside of the Phase 3 study, the following serious adverse reactions were rarely reported: acute febrile neutrophilic dermatosis (Sweet's syndrome), Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome and thrombotic thrombocytopenic purpura.
Ixazomib er ikke substrat for BCRP, MRP2 eller hepatiske OATP'er. 
Ixazomib is not a substrate of BCRP, MRP2 or hepatic OATPs.
Kombinationen af ixazomib og lenalidomid udviste synergistiske cytotoksiske virkninger i myelomatosecellelinjer. 
The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines.
Antiviral profylakse skal overvejes hos patienter, der behandles med ixazomib, for at reducere risikoen for reaktivering af herpes zoster. 
Antiviral prophylaxis should be considered in patients being treated with ixazomib to decrease the risk of herpes zoster reactivation.
Patienterne havde gennemgået et til tre tidligere behandlingsregimer (median på 1), herunder med bortezomib (69%), carfilzomib (< 1%), thalidomid (45%), lenalidomid (12%) og melphalan (81%). 
Patients received one to three prior therapies (median of 1) including prior treatment with bortezomib (69%), carfilzomib (<1%), thalidomide (45%), lenalidomide (12%), melphalan (81%).
• nedsat indhold af kalium i blodet (hypokaliæmi). 
• low levels of potassium in the blood (hypokalaemia)
En planlagt interim-analyse af samlet overlevelse (OS) efter en median opfølgning på 23 måneder blev udført med 35% af det krævede antal dødsfald til den endelige OS-analyse i ITT-populationen: der var 81 dødsfald i ixazomib-gruppen og 90 dødsfald i placebogruppen. 
A planned interim analysis for overall survival (OS) at a median follow up of 23 months was conducted with 35% of the required number of deaths for final OS analysis in the ITT population; there were 81 deaths in the ixazomib regimen and 90 deaths in the placebo regimen.
Det aktive stof ixazomib virker ved at blokere proteasomers virkning. 
Its active substance ixazomib works by blocking the action of proteasomes.
Når ixazomib anvendes i kombination med dexamethason, en svag til moderat induktor af CYP3A4 og andre enzymer og transportører, skal risikoen for reduceret effektivitet af orale kontraceptiva tages i betragtning. 
When ixazomib is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered.
NSMM-5001: Indehaveren af markedsføringstilladelsen skal gennemføre et globalt, prospektivt, ikke-intervenerende observationsstudie hos patienter med myelomatose og frembringe en rapport med deskriptive data fra 1.000 patienter, herunder 200 RRMM-patienter behandlet med ixazomib. 
NSMM-5001: The MAH should conduct a global, prospective, non-interventional, observational study in multiple myeloma patients and provide a report of descriptive data on 1,000 patients including 200 RRMM patients treated with ixazomib.
NINLARO anvendes sammen med lenalidomid (et lægemiddel, som påvirker den måde, immunsystemet fungerer på) og dexamethason (et lægemiddel mod inflammation (betændelseslignende reaktioner)). 
NINLARO is used with lenalidomide (a medicine which affects how your immune system works) and dexamethasone (an anti-inflammatory medicine).
Kapslerne må ikke åbnes eller knuses. 
The capsules should not be opened or crushed.
Takeda GmbH Production Site Singen Robert Bosch Strasse 8 78224 Singen Tyskland 
Takeda GmbH Production Site Singen Robert Bosch Strasse 8 78224 Singen Germany
Ixazomib udviser en multieksponentiel fordelingsprofil. 
Ixazomib exhibits a multi-exponential disposition profile.
• uregelmæssig hjerterytme (arytmi) 
• irregular heart rate (arrhythmia)
Patienter med nedsat nyrefunktion fik en startdosis af lenalidomid i henhold til produktresumeet. 
Patients with renal impairment received a starting dose of lenalidomide according to its SmPC.
• lavt antal trombocytter (trombocytopeni), hvilket kan øge risikoen for næseblod, og at du nemt får blå mærker 
• low platelet counts (thrombocytopenia) which may increase the risk of nose bleeds and you may easily bruise
I studier med ixazomib havde patienter, som fik antiviral profylakse, en lavere forekomst af herpes zoster-infektion sammenlignet med patienter, som ikke fik profylakse. 
Patients included in studies with ixazomib who received antiviral prophylaxis had a lower incidence of herpes zoster infection compared to patients who did not receive prophylaxis.
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) Kapsel, hård 
PHARMACEUTICAL FORM AND CONTENTS Hard capsule
Ixazomib inducerede ikke CYP1A2-, CYP2B6- og CYP3A4/5-aktivitet eller tilhørende immunreaktive proteinniveauer. 
Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5 activity or corresponding immunoreactive protein levels.
Hvis en kapsel går itu, undgå at hvirvle støv op under oprydningen. 
In case of capsule breakage, avoid raising dust during clean-up.
Dag 23 til 28 
Days 23 to 28
Data præsenteret herunder udgør de puljede sikkerhedsdata fra det pivotale globale C16010 fase 3-studie (N = 720) og det dobbeltblinde, placebokontrollerede C16010 China Continuation Study (n = 115). 
The data presented below is the pooled safety data from the pivotal, Phase 3, global C16010 study (n=720) and the double-blind, placebo-controlled C16010 China Continuation Study (n=115).
Efter oral indgivelse blev maksimal ixazomib-plasmakoncentration nået ca. en time efter dosering. 
After oral administration, peak plasma concentrations of ixazomib were achieved at approximately one hour after dosing.
Trombocytter skal monitoreres mindst en gang om måneden under behandling med ixazomib. 
Platelet counts should be monitored at least monthly during ixazomib treatment.
Ixazomib hæmmer ikke P-gp, BCRP, MRP2, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1 eller MATE2-K. Ixazomib forventes ikke at forårsage transportørmedierede lægemiddelinteraktioner. 
Ixazomib is not an inhibitor of P-gp, BCRP, MRP2, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, or MATE2-K. Ixazomib is not expected to cause transporter-mediated drug-drug interactions.
Progressionsfri overlevelse Tilfælde, n (%) Median (måneder) p-værdi* 
Progression-Free Survival Events, n (%)
Behandlingen skal påbegyndes og superviseres af en læge med erfaring i behandling af myelomatose. 
Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma.
Hvis du har lever- eller nyreproblemer, kan lægen udskrive NINLARO-kapsler, der indeholder 3 mg. 
If you have liver or kidney problems, your doctor may prescribe NINLARO capsules containing 3 mg.
Billeddiagnostisk undersøgelse af hjernen (MR-scanning bør foretrækkes) anvendes til at bekræfte diagnosen. 
Brain imaging, preferably Magnetic Resonance Imaging, is used to confirm the diagnosis.
• gulfarvning af øjne og hud (gulsot, hvilket kan være symptom på nedsat leverfunktion) 
• yellow discoloration of eyes and skin (jaundice which could be a symptom of liver impairment)
Tag ikke dobbeltdosis som kompensation for en manglende dosis. 
A double dose should not be taken to make up for a missed dose.
57% af patienterne havde gennemgået stamcelletransplantation. 
Fifty seven percent of patients had undergone prior stem cell transplantation.
Ixazomib påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner. 
Ixazomib has minor influence on the ability to drive or use machines.